PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ — Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged…Original Article
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
